Recombinant Human Anti-CD64 x Human Anti-EGFR Bispecific Antibody (Fv-IgG)  (BSDG-H299)

Recombinant Anti-CD64 x Anti-EGFR Bispecific Antibody (Fv-IgG) is an appended IgG format, which has 2+2 antigen-binding valency. This dual variable domain IgG is generated by appending variable domains of an anti-CD64 IgG with similar domains from an anti-EGFR antibody via short peptide linkers, or vice versa. This BsAb can retarget neutrophils cells to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy.

Datasheet